Abstract
High-dose melphalan and autologous stem cell transplant (SCT) induce hematologic and clinical remissions in AL and results in prolonged survival. In a prior phase II study, we showed that post-SCT adjuvant thalidomide and dexamethasone improved hematologic responses in 42% of patients, resulting in a 39% strictly defined complete response (sCR) rate at 12 months post-SCT (Cohen et al., Br J Haematol 2007;139:224-233). With a median follow-up of 59 months, the overall survival of patients on that study is 69% (Comenzo, Blood 2009;114:3147-3157). We now report on a phase II trial in which we use bortezomib and dexamethasone (BD) following risk-adapted SCT in newly diagnosed patients with amyloidosis who had residual disease following SCT. We show that BD is welltolerated and effective for eradicating persistent clonal plasma cell disease. At 12 months post-SCT, consolidation with BD achieves high overall and unprecedented sCR rates with frequent organ improvement that continues to occur over time.
| Original language | English |
|---|---|
| Pages (from-to) | 135-136 |
| Number of pages | 2 |
| Journal | Amyloid |
| Volume | 18 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - Jun 1 2011 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
Cite this
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. / Landau, H.; Hassoun, H.; Bello, C.; Hoover, E.; Riedel, E. R.; Nimer, Stephen D; Comenzo, R. L.
In: Amyloid, Vol. 18, No. SUPPL. 1, 01.06.2011, p. 135-136.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis
AU - Landau, H.
AU - Hassoun, H.
AU - Bello, C.
AU - Hoover, E.
AU - Riedel, E. R.
AU - Nimer, Stephen D
AU - Comenzo, R. L.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - High-dose melphalan and autologous stem cell transplant (SCT) induce hematologic and clinical remissions in AL and results in prolonged survival. In a prior phase II study, we showed that post-SCT adjuvant thalidomide and dexamethasone improved hematologic responses in 42% of patients, resulting in a 39% strictly defined complete response (sCR) rate at 12 months post-SCT (Cohen et al., Br J Haematol 2007;139:224-233). With a median follow-up of 59 months, the overall survival of patients on that study is 69% (Comenzo, Blood 2009;114:3147-3157). We now report on a phase II trial in which we use bortezomib and dexamethasone (BD) following risk-adapted SCT in newly diagnosed patients with amyloidosis who had residual disease following SCT. We show that BD is welltolerated and effective for eradicating persistent clonal plasma cell disease. At 12 months post-SCT, consolidation with BD achieves high overall and unprecedented sCR rates with frequent organ improvement that continues to occur over time.
AB - High-dose melphalan and autologous stem cell transplant (SCT) induce hematologic and clinical remissions in AL and results in prolonged survival. In a prior phase II study, we showed that post-SCT adjuvant thalidomide and dexamethasone improved hematologic responses in 42% of patients, resulting in a 39% strictly defined complete response (sCR) rate at 12 months post-SCT (Cohen et al., Br J Haematol 2007;139:224-233). With a median follow-up of 59 months, the overall survival of patients on that study is 69% (Comenzo, Blood 2009;114:3147-3157). We now report on a phase II trial in which we use bortezomib and dexamethasone (BD) following risk-adapted SCT in newly diagnosed patients with amyloidosis who had residual disease following SCT. We show that BD is welltolerated and effective for eradicating persistent clonal plasma cell disease. At 12 months post-SCT, consolidation with BD achieves high overall and unprecedented sCR rates with frequent organ improvement that continues to occur over time.
UR - http://www.scopus.com/inward/record.url?scp=79959927379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959927379&partnerID=8YFLogxK
U2 - 10.3109/13506129.2011.574354
DO - 10.3109/13506129.2011.574354
M3 - Article
C2 - 21838462
AN - SCOPUS:79959927379
VL - 18
SP - 135
EP - 136
JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
SN - 1350-6129
IS - SUPPL. 1
ER -